{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:07:28Z","timestamp":1755907648407,"version":"3.44.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.bulcan.2025.05.007","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T07:17:14Z","timestamp":1751872634000},"page":"828-837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["M\u00e9tastases c\u00e9r\u00e9brales dans le cancer du sein\u00a0: diagnostic et prise en charge"],"prefix":"10.1016","volume":"112","author":[{"given":"St\u00e9phanie","family":"B\u00e9court","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Cheymol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Yves","family":"Cren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphaelle","family":"Mouttet-Audouard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2025.05.007_bib0280","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/B978-0-12-811161-1.00002-5","article-title":"Brain metastases: epidemiology","volume":"149","author":"Ostrom","year":"2018","journal-title":"Handb Clin Neurol"},{"issue":"12","key":"10.1016\/j.bulcan.2025.05.007_bib0285","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/s41416-019-0619-y","article-title":"Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort","volume":"121","author":"Darlix","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bulcan.2025.05.007_bib0290","unstructured":"Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer\u00a0\u2013\u00a0PubMed [Internet] [cit\u00e9 14\u00a0d\u00e9cembre 2024]. Disponible sur\u00a0: https:\/\/pubmed.ncbi.nlm.nih.gov\/20308667\/."},{"issue":"1","key":"10.1016\/j.bulcan.2025.05.007_bib0295","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41523-022-00407-z","article-title":"Incidence and impact of brain metastasis in patients with hereditary BRCA1\u00a0or BRCA2\u00a0mutated invasive breast cancer","volume":"8","author":"Garber","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"12","key":"10.1016\/j.bulcan.2025.05.007_bib0300","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/COC.0000000000000466","article-title":"BRCA1\u00a0mutations associated with increased risk of brain metastases in breast cancer: a 1: 2\u00a0matched-pair analysis","volume":"41","author":"Zavitsanos","year":"2018","journal-title":"Am J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2025.05.007_bib0305","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours","volume":"32","author":"Le Rhun","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2025.05.007_bib0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-022-04201-6","article-title":"18F-FET-PET imaging in high-grade gliomas and brain metastases: a systematic review and meta-analysis","volume":"161","author":"Singnurkar","year":"2023","journal-title":"J Neurooncol"},{"key":"10.1016\/j.bulcan.2025.05.007_bib0315","doi-asserted-by":"crossref","first-page":"102860","DOI":"10.1016\/j.ctrv.2024.102860","article-title":"Expert consensus on the prevention of brain metastases in patients with HER2-positive breast cancer","volume":"132","author":"M\u00fcller","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"10.1016\/j.bulcan.2025.05.007_bib0320","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jamaoncol.2019.1838","article-title":"Assessment of molecular relapse detection in early-stage breast cancer","volume":"5","author":"Garcia-Murillas","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bulcan.2025.05.007_bib0325","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1038\/ncomms9839","article-title":"Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma","volume":"6","author":"De Mattos-Arruda","year":"2015","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.bulcan.2025.05.007_bib0330","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/neuonc\/noaa013","article-title":"Subtype switching in breast cancer brain metastases: a multicenter analysis","volume":"22","author":"Hulsbergen","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.bulcan.2025.05.007_bib0335","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.wneu.2021.07.063","article-title":"Comparison of frame-based versus frameless image-guided intracranial stereotactic brain biopsy: a retrospective analysis of safety and efficacy","volume":"164","author":"Ungar","year":"2022","journal-title":"World Neurosurg"},{"issue":"4","key":"10.1016\/j.bulcan.2025.05.007_bib0340","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","article-title":"Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases","volume":"30","author":"Sperduto","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2025.05.007_bib0345","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for brain metastases: ASCO-SNO-ASTRO guideline","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2025.05.007_bib0350","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3\u00a0trial","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2025.05.007_bib0355","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ijrobp.2017.09.047","article-title":"Consensus contouring guidelines for postoperative completely resected cavity stereotactic radiosurgery for brain metastases","volume":"100","author":"Soliman","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.bulcan.2025.05.007_bib0360","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jamaoncol.2018.7204","article-title":"Association of neurosurgical resection with development of pachymeningeal seeding in patients with brain metastases","volume":"5","author":"Cagney","year":"2019","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2025.05.007_bib0365","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ijrobp.2019.03.052","article-title":"Initial SRS for patients with 5\u00a0to 15\u00a0brain metastases: results of a multi-institutional experience","volume":"104","author":"Hughes","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.bulcan.2025.05.007_bib0370","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0360-3016(99)00507-6","article-title":"Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05","volume":"47","author":"Shaw","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.bulcan.2025.05.007_bib0375","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3171\/jns.2006.104.6.907","article-title":"Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin","volume":"104","author":"Vogelbaum","year":"2006","journal-title":"J Neurosurg"},{"issue":"1","key":"10.1016\/j.bulcan.2025.05.007_bib0380","first-page":"CD003869","article-title":"Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases","volume":"1","author":"Tsao","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.bulcan.2025.05.007_bib0385","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/neuonc\/not114","article-title":"Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Brown","year":"2013","journal-title":"Neuro Oncol"},{"issue":"34","key":"10.1016\/j.bulcan.2025.05.007_bib0390","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1200\/JCO.2014.57.2909","article-title":"Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial","volume":"32","author":"Gondi","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2025.05.007_bib0395","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.prro.2022.02.003","article-title":"Radiation therapy for brain metastases: an ASTRO clinical practice guideline","volume":"12","author":"Gondi","year":"2022","journal-title":"Pract Radiat Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2025.05.007_bib0400","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3174\/ajnr.A5472","article-title":"Diagnostic accuracy of amino acid and FDG-PET in differentiating brain metastasis recurrence from radionecrosis after radiotherapy: a systematic review and meta-analysis","volume":"39","author":"Li","year":"2018","journal-title":"AJNR Am J Neuroradiol"},{"issue":"3","key":"10.1016\/j.bulcan.2025.05.007_bib0405","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11060-024-04681-8","article-title":"Impact of concurrent antibody-drug conjugates and radiotherapy on symptomatic radiation necrosis in breast cancer patients with brain metastases: a multicenter retrospective study","volume":"168","author":"Koide","year":"2024","journal-title":"J Neurooncol"},{"issue":"12","key":"10.1016\/j.bulcan.2025.05.007_bib0410","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jamaoncol.2023.4492","article-title":"Symptomatic necrosis with antibody-drug conjugates and concurrent stereotactic radiotherapy for brain metastases","volume":"9","author":"Lebow","year":"2023","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2025.05.007_bib0415","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/14737175.2016.1184572","article-title":"Radionecrosis after stereotactic radiotherapy for brain metastases","volume":"16","author":"Le Rhun","year":"2016","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"10.1016\/j.bulcan.2025.05.007_bib0420","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.trecan.2018.01.003","article-title":"The evolving landscape of brain metastasis","volume":"4","author":"Valiente","year":"2018","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2025.05.007_bib0425","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/annonc\/mdn539","article-title":"Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer","volume":"20","author":"Park","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2025.05.007_bib0430","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211009002","article-title":"Favourable outcome of patients with breast cancer brain metastases treated with dual HER2\u00a0blockade of trastuzumab and pertuzumab","volume":"13","author":"Bergen","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2025.05.007_bib0435","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3\u00a0trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2025.05.007_bib0440","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.breast.2018.07.004","article-title":"T-DM1\u00a0and brain metastases: clinical outcome in HER2-positive metastatic breast cancer","volume":"41","author":"Fabi","year":"2018","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.bulcan.2025.05.007_bib0445","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/annonc\/mdu486","article-title":"Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA","volume":"26","author":"Krop","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2025.05.007_bib0450","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","article-title":"Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer","volume":"15","author":"Lin","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.bulcan.2025.05.007_bib0455","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s11060-011-0629-y","article-title":"Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases","volume":"105","author":"Lin","year":"2011","journal-title":"J Neurooncol"},{"issue":"8","key":"10.1016\/j.bulcan.2025.05.007_bib0460","doi-asserted-by":"crossref","first-page":"e1327","DOI":"10.1002\/onco.13830","article-title":"Efficacy of neratinib plus capecitabine in the subgroup of patients with central nervous system involvement from the NALA trial","volume":"26","author":"Hurvitz","year":"2021","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.bulcan.2025.05.007_bib0465","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.bulcan.2025.05.007_bib0470","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.annonc.2024.08.2347","article-title":"A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases","volume":"35","author":"Andr\u00e9","year":"2024","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2025.05.007_bib0475","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4\u00a0trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat Med"},{"issue":"20","key":"10.1016\/j.bulcan.2025.05.007_bib0480","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1158\/1078-0432.CCR-20-1764","article-title":"A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor-positive breast cancer","volume":"26","author":"Tolaney","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.bulcan.2025.05.007_bib0485","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s13318-020-00635-3","article-title":"Pharmacokinetic and pharmacodynamic studies of elacestrant, a novel oral selective estrogen receptor degrader, in healthy post-menopausal women","volume":"45","author":"Conlan","year":"2020","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"16_suppl","key":"10.1016\/j.bulcan.2025.05.007_bib0490","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1200\/JCO.2024.42.16_suppl.1064","article-title":"Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase 1b\/2\u00a0study","volume":"42","author":"Ibrahim","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2025.05.007_bib0495","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.7314\/APJCP.2013.14.6.3711","article-title":"Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients?","volume":"14","author":"Erten","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.bulcan.2025.05.007_bib0500","first-page":"1638","article-title":"Activity of capecitabine for central nervous system metastases from breast cancer","volume":"17","author":"Gouveia","year":"2023","journal-title":"Ecancermedicalscience"},{"issue":"7","key":"10.1016\/j.bulcan.2025.05.007_bib0505","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamaoncol.2022.0514","article-title":"Treatment with etirinotecan pegol for patients with metastatic breast cancer and brain metastases: final results from the phase 3\u00a0ATTAIN randomized clinical trial","volume":"8","author":"Tripathy","year":"2022","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2025.05.007_bib0510","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10549-017-4304-7","article-title":"Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial","volume":"165","author":"Cort\u00e9s","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"10.1016\/j.bulcan.2025.05.007_bib0515","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1038\/s41591-023-02392-7","article-title":"Pembrolizumab in brain metastases of diverse histologies: phase 2\u00a0trial results","volume":"29","author":"Brastianos","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.bulcan.2025.05.007_bib0520","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.bulcan.2025.05.007_bib0525","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2025.05.007_bib0530","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1159\/000540257","article-title":"Case report of complete response to olaparib in a patient with breast cancer brain metastases","volume":"17","author":"Asazuma","year":"2024","journal-title":"Case Rep Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2025.05.007_bib0535","doi-asserted-by":"crossref","first-page":"102995","DOI":"10.1016\/j.esmoop.2024.102995","article-title":"The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients-a multicenter real-world analysis","volume":"9","author":"Dannehl","year":"2024","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.bulcan.2025.05.007_bib0540","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s12282-024-01565-7","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases","volume":"31","author":"De Moura","year":"2024","journal-title":"Breast Cancer"},{"issue":"9","key":"10.1016\/j.bulcan.2025.05.007_bib0545","doi-asserted-by":"crossref","first-page":"103699","DOI":"10.1016\/j.esmoop.2024.103699","article-title":"Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial","volume":"9","author":"Vaz Batista","year":"2024","journal-title":"ESMO Open"},{"issue":"34","key":"10.1016\/j.bulcan.2025.05.007_bib0275","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.2217\/fon-2021-0753","article-title":"Alliance A011801 (compassHER2\u00a0RD): postneoadjuvant T-DM1\u00a0+ tucatinib\/placebo in patients with residual HER2-positive invasive breast cancer","volume":"17","author":"O'Sullivan","year":"2021","journal-title":"Future Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125002644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125002644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T13:22:40Z","timestamp":1755868960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455125002644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":55,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0007455125002644"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.05.007","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"M\u00e9tastases c\u00e9r\u00e9brales dans le cancer du sein\u00a0: diagnostic et prise en charge","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}